Literature DB >> 14514352

Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level.

Salomé Veiga1, Sónia Henriques, Nuno C Santos, Miguel Castanho.   

Abstract

Partition of the intrinsically fluorescent HIV fusion inhibitor enfuvirtide into lipidic membranes is relatively high (Delta G =6.6 kcal x mol(-1)) and modulated by cholesterol. A shallow position in the lipidic matrix makes it readily available for interaction with gp41. No conformational energetic barrier prevents enfuvirtide from being active in both aqueous solution and lipidic membranes. Lipidic membranes may play a key role in the enfuvirtide biochemical mode of action.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14514352      PMCID： PMC1223848          DOI： 10.1042/BJ20031350

Source DB:  PubMed          Journal:  Biochem J        ISSN： 0264-6021            Impact factor:   3.857


  10 in total

1.  Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage.

Authors:  Y Kliger; S A Gallo; S G Peisajovich; I Munoz-Barroso; S Avkin; R Blumenthal; Y Shai
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

2.  Joint determination by Brownian dynamics and fluorescence quenching of the in-depth location profile of biomolecules in membranes.

Authors:  M X Fernandes; J García de la Torre; M A R B Castanho
Journal:  Anal Biochem       Date:  2002-08-01       Impact factor: 3.365

Review 3.  Quantifying molecular partition into model systems of biomembranes: an emphasis on optical spectroscopic methods.

Authors:  Nuno C Santos; Manuel Prieto; Miguel A R B Castanho
Journal:  Biochim Biophys Acta       Date:  2003-06-10

4.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

Authors:  M Lu; S C Blacklow; P S Kim
Journal:  Nat Struct Biol       Date:  1995-12

5.  Resonance energy transfer in a model system of membranes: application to gel and liquid crystalline phases.

Authors:  L M Loura; A Fedorov; M Prieto
Journal:  Biophys J       Date:  1996-10       Impact factor: 4.033

6.  Combined Monte Carlo and molecular dynamics simulation of fully hydrated dioleyl and palmitoyl-oleyl phosphatidylcholine lipid bilayers.

Authors:  S W Chiu; E Jakobsson; S Subramaniam; H L Scott
Journal:  Biophys J       Date:  1999-11       Impact factor: 4.033

7.  Vesicles of variable sizes produced by a rapid extrusion procedure.

Authors:  L D Mayer; M J Hope; P R Cullis
Journal:  Biochim Biophys Acta       Date:  1986-06-13

Review 8.  Peptide and non-peptide HIV fusion inhibitors.

Authors:  Shibo Jiang; Qian Zhao; Asim K Debnath
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

9.  Interaction of the major epitope region of HIV protein gp41 with membrane model systems. A fluorescence spectroscopy study.

Authors:  N C Santos; M Prieto; M A Castanho
Journal:  Biochemistry       Date:  1998-06-16       Impact factor: 3.162

10.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Authors:  Jacob P Lalezari; Keith Henry; Mary O'Hearn; Julio S G Montaner; Peter J Piliero; Benôit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245
  10 in total
  20 in total

Review 1.  Lipid membrane-induced optimization for ligand-receptor docking: recent tools and insights for the "membrane catalysis" model.

Authors:  Miguel A R B Castanho; Miguel X Fernandes
Journal:  Eur Biophys J       Date:  2005-10-11       Impact factor: 1.733

2.  In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence.

Authors:  T N Figueira; L M Palermo; A S Veiga; D Huey; C A Alabi; N C Santos; J C Welsch; C Mathieu; B Horvat; S Niewiesk; A Moscona; M A R B Castanho; M Porotto
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

3.  HIV-1 entry in SupT1-R5, CEM-ss, and primary CD4+ T cells occurs at the plasma membrane and does not require endocytosis.

Authors:  Nikolas Herold; Maria Anders-Ößwein; Bärbel Glass; Manon Eckhardt; Barbara Müller; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

4.  The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.

Authors:  Yuanmei Zhu; Xiaohui Ding; Danwei Yu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

5.  HIV Fusion in Dendritic Cells Occurs Mainly at the Surface and Is Limited by Low CD4 Levels.

Authors:  Lise Chauveau; Daniel Aaron Donahue; Blandine Monel; Francoise Porrot; Timothée Bruel; Lea Richard; Nicoletta Casartelli; Olivier Schwartz
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

Review 6.  HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2007-03-01       Impact factor: 2.332

7.  Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure.

Authors:  Marcelo T Augusto; Axel Hollmann; Miguel A R B Castanho; Matteo Porotto; Antonello Pessi; Nuno C Santos
Journal:  J Antimicrob Chemother       Date:  2014-01-23       Impact factor: 5.790

8.  HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes.

Authors:  Pedro M Matos; Miguel A R B Castanho; Nuno C Santos
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

9.  Effective in Vivo Targeting of Influenza Virus through a Cell-Penetrating/Fusion Inhibitor Tandem Peptide Anchored to the Plasma Membrane.

Authors:  T N Figueira; M T Augusto; K Rybkina; D Stelitano; M G Noval; O E Harder; A S Veiga; D Huey; C A Alabi; S Biswas; S Niewiesk; A Moscona; N C Santos; M A R B Castanho; M Porotto
Journal:  Bioconjug Chem       Date:  2018-09-14       Impact factor: 4.774

10.  A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion.

Authors:  Frederic Vigant; Jihye Lee; Axel Hollmann; Lukas B Tanner; Zeynep Akyol Ataman; Tatyana Yun; Guanghou Shui; Hector C Aguilar; Dong Zhang; David Meriwether; Gleyder Roman-Sosa; Lindsey R Robinson; Terry L Juelich; Hubert Buczkowski; Sunwen Chou; Miguel A R B Castanho; Mike C Wolf; Jennifer K Smith; Ashley Banyard; Margaret Kielian; Srinivasa Reddy; Markus R Wenk; Matthias Selke; Nuno C Santos; Alexander N Freiberg; Michael E Jung; Benhur Lee
Journal:  PLoS Pathog       Date:  2013-04-18       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.